We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$291M
AUM Growth
+$25.4M
Cap. Flow
-$37.9M
Cap. Flow %
-13.02%
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$6.64M
2
AFMD
Affimed
AFMD
+$3.03M
3
STIM icon
Neuronetics
STIM
+$1.8M
4
OTIC
Otonomy, Inc.
OTIC
+$1.15M
5
KURA icon
Kura Oncology
KURA
+$1.03M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$12M
2
WVE icon
Wave Life Sciences
WVE
+$3.94M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$3.57M
5
ARDX icon
Ardelyx
ARDX
+$2.31M

Sector Composition

Rank Sector Weight
1 Healthcare 91.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYBX
51
DELISTED
Synlogic
SYBX
$1.29M 0.44%
33,382
+4,527
+16% +$152K
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$1.25M 0.43%
40,657
-129,143
-76% -$3.57M
MDGL icon
53
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.24M 0.43%
13,600
+7,000
+106% +$679K
PRVL
54
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.19M 0.41%
75,000
– –
NXTC icon
55
NextCure
NXTC
$16.8M
$1.13M 0.39%
+1,667
New +$836K
GNCA
56
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.12M 0.39%
542,564
– –
SCYX icon
57
SCYNEXIS
SCYX
$48.1M
$1.1M 0.38%
15,093
-819
-5% -$67.5K
ARGX icon
58
argenx
ARGX
$53.4B
$975K 0.33%
6,071
-15,898
-72% -$2.15M
TPST icon
59
Tempest Therapeutics
TPST
$13.7M
$873K 0.3%
+664
New +$936K
CTMX icon
60
CytomX Therapeutics
CTMX
$675M
$831K 0.29%
100,000
– –
XCUR icon
61
Exicure
XCUR
$10.2M
$787K 0.27%
+1,833
New +$750K
ASMB icon
62
Assembly Biosciences
ASMB
$498M
$728K 0.25%
2,964
-1,250
-30% -$230K
INSM icon
63
Insmed
INSM
$21.4B
$716K 0.25%
30,000
– –
GMDA
64
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$640K 0.22%
148,781
-124,128
-45% -$591K
MORF
65
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$635K 0.22%
+37,000
New +$577K
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
$621K 0.21%
4,339
-15,730
-78% -$1.15M
MASI
67
DELISTED
Masimo
MASI
$474K 0.16%
3,000
– –
GRTS
68
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$449K 0.15%
50,000
– –
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$444K 0.15%
22,000
– –
KALV
70
DELISTED
KalVista Pharmaceuticals
KALV
$440K 0.15%
24,725
– –
STRO icon
71
Sutro Biopharma
STRO
$401M
$440K 0.15%
4,000
– –
LRMR icon
72
Larimar Therapeutics
LRMR
$397M
$339K 0.12%
25,458
– –
RIGL icon
73
Rigel Pharmaceuticals
RIGL
$681M
$337K 0.12%
15,770
– –
ADXS
74
DELISTED
Advaxis Inc
ADXS
$300K 0.1%
350,000
– –
WVE icon
75
Wave Life Sciences
WVE
$1.09B
$296K 0.1%
36,960
-160,594
-81% -$3.94M
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, DAFNA Capital Management held 96 positions worth $291M, up 9.6% from $266M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management withdrew a net $37.9M in Q4 2019, closing 15 positions and reducing 27 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Affimed worth $3.11M.

  • DAFNA Capital Management's largest Q4 2019 buy was Affimed: 113,356 shares worth $3.11M.
  • DAFNA Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $6.64M increase.
  • DAFNA Capital Management's biggest Q4 2019 reduction was Wave Life Sciences, cutting an estimated $3.94M.
  • DAFNA Capital Management fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $12M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $291M portfolio in Q4 2019.
  • DAFNA Capital Management opened 7 new positions and closed 15 in Q4 2019.
  • DAFNA Capital Management's portfolio value rose 9.6% quarter-over-quarter to $291M.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.